Intratumoral Administration of Holmium-166 Acetylacetonate Microspheres: Antitumor Efficacy and Feasibility of Multimodality Imaging in Renal Cancer

Abstract

Purpose

The increasing incidence of small renal tumors in an aging population with comorbidities has stimulated the development of minimally invasive treatments. This study aimed to assess the efficacy and demonstrate feasibility of multimodality imaging of intratumoral administration of holmium-166 microspheres (166HoAcAcMS). This new technique locally ablates renal tumors through high-energy beta particles, while the gamma rays allow for nuclear imaging and the paramagnetism of holmium allows for MRI.

Methods

166HoAcAcMS were administered intratumorally in orthotopic renal tumors (Balb/C mice). Post administration CT, SPECT and MRI was performed. At several time points (2 h, 1, 2, 3, 7 and 14 days) after MS administration, tumors were measured and histologically analyzed. Holmium accumulation in organs was measured using inductively coupled plasma mass spectrometry.

Results

166HoAcAcMS were successfully administered to tumor bearing mice. A striking near-complete tumor-control was observed in 166HoAcAcMS treated mice (0.10±0.01 cm3 vs. 4.15±0.3 cm3 for control tumors). Focal necrosis and inflammation was present from 24 h following treatment. Renal parenchyma outside the radiated region showed no histological alterations. Post administration CT, MRI and SPECT imaging revealed clear deposits of 166HoAcAcMS in the kidney.

Conclusions

Intratumorally administered 166HoAcAcMS has great potential as a new local treatment of renal tumors for surgically unfit patients. In addition to strong cancer control, it provides powerful multimodality imaging opportunities.

About the Authors:

Wouter Bult

Contributed equally to this work with: Wouter Bult, Stephanie G. C. Kroeze, Judith J. M. Jans

Affiliations Imaging Division, Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands, Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, Groningen, The Netherlands

Stephanie G. C. Kroeze

Contributed equally to this work with: Wouter Bult, Stephanie G. C. Kroeze, Judith J. M. Jans

Affiliations Department of Urology, University Medical Center Utrecht, Utrecht, The Netherlands, Laboratory of Experimental Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

Mattijs Elschot

Affiliation: Imaging Division, Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands

Peter R. Seevinck

Affiliation: Image Sciences Institute, University Medical Center Utrecht, Utrecht, The Netherlands

Freek J. Beekman

Affiliations Milabs, Utrecht, The Netherlands, Section Radiation Detection & Medical Imaging, Faculty of Applied Sciences, Delft University of Technology, Delft, The Netherlands

Hugo W. A. M. de Jong

Affiliation: Imaging Division, Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands

Donald R. A. Uges

Affiliation: Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, Groningen, The Netherlands

Jos G. W. Kosterink

Affiliation: Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, Groningen, The Netherlands

Peter R. Luijten

Affiliation: Imaging Division, Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands

Wim E. Hennink

Affiliation: Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

Alfred D. van het Schip

Affiliation: Imaging Division, Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands

J. L. H. Ruud Bosch

Affiliation: Department of Urology, University Medical Center Utrecht, Utrecht, The Netherlands

J. Frank W. Nijsen

* E-mail: [email protected]

Affiliation: Imaging Division, Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands

Judith J. M. Jans

Contributed equally to this work with: Wouter Bult, Stephanie G. C. Kroeze, Judith J. M. Jans

Affiliations Department of Urology, University Medical Center Utrecht, Utrecht, The Netherlands, Laboratory of Experimental Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

Introduction

Kidney cancer accounts for approximately 3% of all cancers. With a world-wide incidence of 208,000 new cases and a mortality of 102,000 patients each year, it is one of the most lethal genitourinary malignancies [1]. In recent years a dramatic increase of incidentally detected small renal tumors has occurred, mainly due to more widespread use of non-invasive imaging techniques. These tumors are frequently found in patients who are at surgical risk due to factors such as advanced age and comorbidities [2]. It has been shown that not every patient will benefit from surgical resection of the tumor and that it is better to avoid surgically-induced morbidity in several cases [3], [4], [5]. The recommended treatment for small renal tumors is nephron-sparing surgery [6], but for patients for whom surgical resection is considered inappropriate, minimally invasive techniques are also being developed [7], [8]. Although historically external beam radiotherapy (EBRT) has not been effective for treatment of renal tumors due to breathing-related movement of the kidneys and radiosensitivity of adjacent tissue, new radiation methods may provide a successful alternative [9]. An important new development to circumvent the radiosensitivity issues of healthy tissue around the tumor is the selective local administration of radioactive sources to the tumor [10], [11]. An example of this selective local administration is transcatheter radioembolization with yttrium-90 (90Y) resin and glass microspheres (MS), which has shown promising results in treatment of unresectable hepatic metastases [12], [13], [14]. Possibly, intratumoral injection might be more effective than intra-arterial injection [15]. In this paper, a novel local ablation technique is presented using small (10–15 µm) holmium-166 acetylacetonate microspheres (166HoAcAcMS) with a high holmium load [16]. 166Ho emits both high-energy beta particles (Eβmax 1.77 and 1.85 MeV, maximum tissue penetration 8 mm, mean tissue penetration 2.5 mm) and gamma rays (0.081 MeV) that allow for nuclear imaging and has a half-life of 26.8 h [17]. Moreover, non-radioactive holmium-165 can be visualized by CT and MRI, due to its high mass attenuation coefficient and its paramagnetic properties, respectively [18]. These imaging opportunities offer many advantages such as visualizing the distribution of holmium microspheres inter- and post-treatment for direct therapy evaluation and follow-up, as well as MRI-based absorbed dose estimation [19]. This study provides a proof of principle for intratumoral administration of 166HoAcAcMS as a novel treatment strategy for kidney cancer in patients not eligible for surgery, and demonstrates the elegant in vivo multimodality imaging necessary for treatment guidance and monitoring.

Materials and Methods

Cell culture

Balb/C renal carcinoma cells (Renca, National Cancer Institute, USA) were maintained at 37°C and 5% CO2 in Dulbecco's Modified Eagle's Medium (Lonza, the Netherlands) supplemented with 10% fetal bovine serum (Lonza, the Netherlands), 1% penicillin/streptomycin and 1% glutamine. To prepare for in vivo transplantation, cells were trypsinized, washed and kept on ice until transplantation.

Ethics Statement

All experimental protocols were conducted in agreement with the Netherlands Experiments on Animals Act and the European convention guidelines, and accepted by the Animal Experiments Committee Utrecht, the Netherlands (2009.III.01.003).

Animal experiments

Male Balb/C mice (Charles River, the Netherlands) aged 9–11 weeks were used for experiments. All surgical procedures were performed under isoflurane anesthesia (IsoFlo, Abbott Animal Health, the Netherlands). To provide analgesia each mouse received 3 µg buprenorfine subcutaneously (Buprecare, AST Pharma, the Netherlands) prior to, and 24 h post surgery.

Orthotopic kidney tumor model

In 60 mice, the left kidney was exposed through a flank incision and a Renca tumor cube of 2 mm diameter was transplanted under the renal capsule. Renal tumors were allowed to grow for 1 week, while well being of mice was followed by measuring body weight and scoring physical appearance.

Holmium acetylacetonate MS

HoAcAcMS were prepared as described by Bult et al [17]. In short, HoAcAcMS were prepared using a solvent evaporation technique. Holmium acetylacetonate was dissolved in chloroform (HPLC grade, Sigma Aldrich, The Netherlands), followed by emulsification in water containing 2% polyvinylalcohol (average MW 30,000–70,000 Da, Sigma Aldrich, The Netherlands) as an emulsifier. After evaporation of chloroform under continuous stirring, HoAcAcMS were harvested and washed with water before sieving to obtain the preferred particle size (10–15 um). The sieve fractions were dried at 40°C. The particle size was determined using a Coulter Counter, and the holmium content was determined using the complexometric titration as described by Zielhuis et al. [20]. Sixty mg HoAcAcMS was transferred to a high-density poly-ethylene vial (Posthumus Plastics, the Netherlands), and neutron irradiated for one hour with a thermal neutron flux of 5×1012 n cm−2 s−1, using the pneumatic rabbit system in a nuclear reactor (Reactor Institute Delft, the Netherlands) to render the MS radioactive. Radionuclidic purity was determined batchwise after neutron activation to 166HoAcAcMS. Analysis was done by gamma spectroscopy using a high-purity germanium detector and GammaVision software. The gamma spectrum obtained was compared to reference data for holmium-166 from ICRP 38 (ICRP, 1983. Radionuclide Transformations – Energy and Intensity of Emissions. ICRP Publication 38. Ann. ICRP 11–13). For the batch of 165HoAcAcMS used in this study no peaks other than from holmium-166 were detectable after neutron activation.

To assess the MS integrity after neutron irradiation particle size was determined using a coulter counter (Multisizer 3, Beckman Coulter, the Netherlands), performing light microscopy and electron microscopy (Phenom, Phenom B.V., the Netherlands). The size of the HoAcAcMS used range from 10–15 µm. Earlier in vitro and in vivo stability studies conducted with these HoAcAcMS before and after neutron irradiation have been described in detail by Bult et al. [21]. Briefly, in vitro release of holmium was assessed after incubation at 37°C in phosphate buffer for 24 hours up to 180 days showing <0.3% and <0.5% free holmium, respectively. HoAcAcMS before and after neutron irradiation were also administered intratumorally in VX2 tumor-bearing rabbits. No holmium was detected in the faeces, urine, femur and blood of the rabbits, and histological examination of the tumor revealed clusters of intact microspheres amidst necrotic tissue after thirty days. These studies have shown that the radiochemical purity and stability of the HoAcAcMS is high and diffusion throughout the tissue is not expected.

Administration of microspheres

Radioactive 166HoAcAcMS (600 MBq) were suspended in 1.2 ml of an aqueous poloxamer F68 solution (Pluronic® solution, 2% w/v), and 50 µl was taken up in 29 G insulin syringes (Becton Dickinson Ultra Fine, the Netherlands). The activity was measured using a dose calibrator (VDC-404, Veenstra Instruments, the Netherlands). Prior to administration, the syringes were placed in an acrylic glass cylinder to limit the dose to the hands. The syringe was agitated vigorously to obtain a homogenous suspension and 10 µl of the 166HoAcAcMS (approximately 5 MBq or 500 µg MS) suspension was administered intratumorally via an open surgical approach (n = 4–5/group). After administration the syringes were measured in a dose calibrator to calculate the dose administered to the tumors. Control mice (n = 3–7/group) received intratumoral administration of 0.9% NaCl. At 2 hours, 1, 2, 3, 7 and 14 days after administration of MS mice were sacrificed by cervical dislocation.

Imaging

Immediately following administration of 166HoAcAcMS, anesthetized mice were placed in a small animal CT (U-CT, MILabs, the Netherlands). Images were acquired at a tube voltage of 45 kV, a tube current of 350 mAs and a voxel size of 83 µm (isotropic). Two mice underwent multimodality imaging. Single Photon Emission Computed Tomography imaging (SPECT) was performed on a U-SPECT system (MILabs, the Netherlands) with a general purpose mouse collimator (75 focussing 0.6 mm diameter pinholes) to assess the 166HoAcAcMS distribution on a sub-half-millimeter resolution [22]. Images were reconstructed using previously described methods [23], and compensated for distance dependent sensitivity and blurring of the projection of the pinholes during reconstruction through point source based system calibration [24]. The images were registered using an automated registration programme, using set reference points/bed positions. From the SPECT images, the dose distribution could be calculated as described by the MIRD S-voxel method [25]. The MCNPX 2.5.0 Monte Carlo Code [26] was used to estimate the 166Ho dose convolution kernel. For each voxel in a 15.375 mm3 cube of tissue material (ρ = 1.06 g cm−1) the absorbed dose was calculated as a result of the 166Ho source uniformly distributed in the center voxel of the cube. The voxel size chosen was 375 µm (isotropic), equal to the voxel size of the reconstructed SPECT images. Dose maps were calculated by convolution of the SPECT images with a simulated 166Ho dose kernel. MRI was performed on a 4.7 T horizontal bore small animal scanner (Agilent, UK). Images were acquired using a multi-slice gradient echo MR sequence with an echo time of 3.0 msec and repetition time of 242 msec, a field of view (FOV) of 64×32 mm2, a scan matrix of 256×128 with 38 slices resulting in a voxel size of 0.25×0.25×0.5 mm3, eight signal averages and a 25° flip angle.

Histopathologic analysis

Tumor-bearing and contralateral kidney, liver, spleen and heart/lung were weighed and radioactivity was measured in a dose calibrator for qualitative purposes. Quantification of holmium was performed by inductively coupled plasma mass spectrometry. Tumor size was measured using digital callipers and tumor volumes were calculated using the equation V = (A×0.5)×B2 (A = largest diameter, B = smallest diameter). Tumor-bearing kidneys were processed and embedded in paraffin. A haematoxylin and eosin (HE) section of each kidney was evaluated for glomerular, tubular and vascular changes and inflammation of the irradiated tumor and surrounding renal parenchyma, as previously described [27], [28].

Inductively coupled plasma mass spectrometry

Inductively coupled plasma mass spectrometry (ICP MS) was performed to determine the holmium content in the organs used for histopathologic analysis after NaCl or 166HoAcAcMS treatment. Paraffin was removed from embedded tissue by gentle heating. The organs were digested in 1 mL aqua regia (concentrated nitric, perchloric, and sulphuric acid in a ratio 4∶1∶1) under heating. After destruction, all samples were passed through cotton gauze to remove the insoluble paraffin residue. The samples were diluted in 2% nitric acid, and measured on a Varian 820 MS (Varian, the Netherlands), with a detection limit of 0.1 nanogram holmium mL−1 using standard holmium reference material (CertiPUR Holmium ICP Standard (traceable to SRM from NIST), Merck, Darmstadt, Germany).

Results

Microsphere administration

MS had a smooth surface, both before and after neutron irradiation and holmium content of the MS was 45% (w/w). The size distribution was not affected by neutron irradiation, and the specific activity of the 166HoAcAcMS was 10 MBq mg−1 corresponding with 22 Bq ng−1 holmium at the time of delivery. 166HoAcAcMS were successfully administered to 24 Renca tumor-bearing Balb/C mice. As a control, 36 (n = 3–7 mice per time point) tumor-bearing animals received 10 µl of saline. The mean tumor diameter at the time of treatment was 5.6 mm±1.6 mm. The average administered dose was 2.7 MBq±1.2 MBq (corresponding to 270±120 µg 166HoAcAcMS). Hence the detection limit expressed as percentage of the injected dose of holmium was 0.9×10−4%.

Efficacy

Neither discomfort nor aberrant behaviour was observed in these mice. The bodyweight of mice in the 166HoAcAcMS (22.2±1.8 g) and saline group (22.1±1.2 g) remained constant throughout the experiment. The efficacy of 166HoAcAcMS after intratumoral injection is depicted in Figure 1A. The tumor volume in the saline control group increased from 0.12±0.03 cm3 (day 3 after treatment) to 4.15±0.3 cm3 two weeks post injection. Importantly, the tumor volume in the 166HoAcAcMS group remained constant from 0.14±0.01 cm3 at three days post injection to 0.10±0.01 cm3 after two weeks. ICP MS analysis showed that 72.9% (33.1–83.6) (median (IQR)) of the total holmium measured was detected in the tumors of mice that received 166HoAcAcMS. In 15 mice in the holmium group 16.9% (IQR 2.6–52.5) holmium was found in the lungs, most likely due to the inadvertent delivery of 166HoAcAcMS in a blood vessel in or around the tumor [14].

[Figure omitted. See PDF.]

Figure 1. Intratumoral injection of 166HoAcAcMS is an effective, minimally invasive procedure in kindney cancer.

(A) Tumor volume at different time points after treatment. The solid line represents the tumor volume of the 166HoAcAcMS group. The dashed line represents the tumor volume of the saline control group. (B) HE staining of kidney and tumor tissue 2 weeks after 166HoAcAcMS treatment (n indicates normal kidney, t indicates tumor.) (C) HE staining (20×) of renal parenchyma outside the radiated region 2 weeks following 166HoAcAcMS administration, showing no glomerular, tubular or vascular alterations. (D) HE staining (20×) of irradiated tumor 1 day following 166HoAcAcMS administration. HoAcAcMS are present as focal intratumoral deposits (arrows). At the site of injection, tumor necrosis and cell death is visible. (E) HE staining of irradiated tumor (20×) 2 days following 166HoAcAcMS administration. Inflammatory cells are present at the radiated area. (F) HE staining of irradiated tumor (20×) 1 week after 166HoAcAcMS administration. Grade 3 radiation damage [27] is only visible in renal parenchyma directly surrounding the tumor.

https://doi.org/10.1371/journal.pone.0052178.g001

Histology

166HoAcAcMS were present as focal intratumoral deposits (Figure 1D). Tumor necrosis was visible at the site of injection from 24 h following 166HoAcAcMS administration (Figure 1D), inflammatory cells were visible within 48 h (Figure 1E). Grade 3 radiation damage [27] was only visible in renal parenchyma directly surrounding the tumor 2 weeks after treatment (Figure 1F). In all cases, renal parenchyma outside the radiated region showed no glomerular, tubular or vascular alterations (Figure 1A).

Imaging

The powerful multimodality imaging characteristics of holmium were demonstrated with CT, SPECT and MRI in mice that were terminated immediately following intratumoral administration of 166HoAcAcMS (Figure 2A to D). CT imaging revealed deposits of 166HoAcAcMS (approximately 300 µg, corresponding to 2.7 MBq 166Ho) in the kidney area. Substantial accumulation of particles was seen at the site of injection (Figure 2B). 166HoAcAcMS were clearly visualized using SPECT imaging and the SPECT images served as a template for the construction of a dose map (Figure 2E). The dose map shows a selective deposition of therapeutic beta particles at the site of injection, leading to a local tumor absorbed dose in excess of 2200 Gy. The average tumor dose was calculated using the equation as postulated by Vente et al.: Dose (Gy) = (Dosage administered (MBq) ×15.87 mJ MBq−1)/tumor weight (g) [29]. The calculated average tumor dose in this study was 323 Gy. The radiation dose to the healthy tissue was below 23 Gy in the largest part of the kidney and surrounding organs (Figure 2F). For a more detailed anatomical depiction of the soft tissue, MR images were acquired. On T2* weighted MRI scans, holmium causes a rapid signal decay due to the paramagnetic nature of this element. Consequently, holmium appears as blackening on T2* weighted images. As can be seen in Figure 3, holmium is clearly visible as a dark spot in the upper side of the kidney, where it was administered in the tumor. By combining the sensitivity and high quantitative accuracy of SPECT imaging [30], [31], [32] with the soft tissue imaging of MRI, the 166HoAcAcMS therapy can accurately be evaluated to ensure complete tumor ablation.

[Figure omitted. See PDF.]

Figure 2. An example of the multimodality imaging characteristics of intratumorally administered 166HoAcAcMS.

Images are acquired immediately following administration of the MS. (A) A schematic representation of the mouse anatomy (I: Lungs; II: Liver; III: Stomach; IV: Kidney; *: Artefact caused by holmium on MRI image 3C) (B) CT image, depicting the HoAcAcMS in the kidney area as a white area (arrow). (C) MR image showing the soft tissue detail of this imaging modality and the deposition of HoAcAcMS as a dark spot. (D) SPECT image, showing a selective visualisation of radioactive MS in the kidney area. (E) Fused SPECT and CT image. (F) MRI image fused with the dose map, showing the absorbed dose distribution in the kidney area.

https://doi.org/10.1371/journal.pone.0052178.g002

[Figure omitted. See PDF.]

Figure 3. Schematic drawing showing the percutaneous approach to 166HoAcAcMS administration.

The patient is placed in lateral position in an angiography suite. The 166HoAcAcMS are administered intratumorally by a shielded syringe under real-time CT guidance.

https://doi.org/10.1371/journal.pone.0052178.g003

Discussion

The feasibility and efficacy of 166HoAcAcMS as a minimally invasive treatment was assessed in a mouse model for kidney cancer. Importantly, the intratumoral administration of 2.7 MBq 166HoAcAcMS arrested tumor growth, which was apparent one week post-administration when approximately 95% of the ionizing radiation dose has been delivered. Assuming all beta energy is deposited in the tumor, the calculated average tumor absorbed dose was 323 Gy, with local doses as high as 2200 Gy. The average tumor absorbed dose is approximately 4–5 fold higher than the 60–80 Gy absorbed dose used in EBRT as a value sufficient for complete tumor kill. Despite the high calculated absorbed dose, the localized nature of the radiation dose considerably reduces unwanted damage of surrounding tissues. The radiation dose to the healthy tissue was below 23 Gy in the largest part of the kidney and surrounding organs. 23 Gy is the maximum tolerance dose for uniform kidney irradiation [33]. Given the maximum penetration depth of the emitted beta particles (8 mm) and the larger size of the kidney, the radiation dose to healthy parenchyma is expected to be negligible when translating to the clinical situation.

In addition to efficacy, the feasibility of multimodality imaging of 166HoAcAcMS was demonstrated. Deposits of approximately 2.7 MBq or 270 micrograms of 166HoAcAcMS were clearly visible on SPECT, or CT and MRI. 166HoAcAcMS can therefore be regarded as a true multimodality imaging agent. The specificity of SPECT was superior to that of both CT and MRI. In this study CT imaging was used to determine the distribution of 166HoAcAcMS, since the low amounts of activity administered result in a long acquisition time with SPECT (6 minutes for CT versus 45 minutes SPECT). However, in patients faster SPECT image acquisition will be possible, as the amount of activity will be 20- to 100-fold higher. Furthermore, by combining the sensitivity and high quantitative accuracy of SPECT imaging [30], [31], [32] with the soft tissue imaging of MRI, the 166HoAcAcMS therapy could accurately be evaluated to ensure complete tumor ablation during the procedure.

The use of radioactive microspheres in the treatment of an experimental tumor model was successful, and results are very promising. Although the orthotopic mouse model resembles the human situation in many aspects, a number of points need to be addressed before intratumoral administration of 166HoAcAcMS could be routinely applied in humans. First of all, toxicity studies should be performed in humans. The in vivo stability of the HoAcAcMS was assessed in a tumor bearing rabbit model, which showed the stability of the HoAcAcMS for up to one month, and no toxicity was observed [21]. Radioactive holmium poly(L-lactic acid) particles of 20–50 µm for intra-arterial application have been evaluated for biodistribution, efficacy and toxicity in rats, rabbits and pigs, and have shown their stability and safety [29], [34], a phase-I study of patients with liver metastases has recently been performed [35], [36]. Similar toxicity experiments will need to be performed for the 166HoAcAcMS described here prior to initiating a clinical trial.

Tumors in study ranged from 4 to 8 mm at the time of treatment, which is similar to the penetration range of the beta particles in tissue. It is expected that for nephron-sparing treatment of tumors smaller than 4 cm, 4 to 8 injections with 166HoAcAcMS are required for an effective eradication. This is comparable to conventional minimally invasive ablative treatments that often need multiple probes to achieve complete tumor kill [37]. The advantage of radionuclide therapy compared to thermal ablative minimally invasive techniques is the prolonged delivery of energy to the tumor tissue, due to the half life. Using multiple deposits of 166HoAcAcMS, an accurate delivery of the dose can be given independent of shape and size of the tumor. As observed, an average tumor dose of 323 Gy was obtained with one deposit. When positioning the deposits within 1 cm apart it is expected that complete tumor kill can be achieved. However, more research is warranted to further investigate the relationship between deposit localisation and tumor kill in larger tumors.

A technical problem we encountered was the delivery of approximately 50% of the intended dose (5 MBq), possibly due to adsorption of radioactive MS onto the syringe wall and dosage errors due to the small injected volume. When treating patients, the administered volume is higher, resulting in a smaller difference between aimed and actual administered dose. Furthermore, varying concentrations of holmium were found in the lungs of several mice. Tumor vascularity as well as particle size is an important factor for the fate of the radioactivity [38]. Although the presence of holmium in the lungs is likely due to the inadvertent vascular delivery of the MS during the intratumoral injections [14] and with a size of 12.5 µm diffusion within the tissue is less likely, a future study should be performed to examine these two factors specifically. Lung uptake was not observed when administering 166HoAcAcMS percutaneously under ultrasound guidance in hypervascular feline liver tumors [38]. Ultrasound guidance not only helps to distinguish healthy tissue from tumorous tissue, it also visualises tumor vasculature. Unfortunately, percutaneous ultrasound guided administration was not feasible in this model. Nevertheless, in patients the procedure should be performed percutaneously under CT or ultrasound guidance, to ensure accurate delivery and avoid inadvertent vascular delivery. An illustration of a CT guided approach is shown in Figure 3. A new method that could be used is the multiplanar Global Positioning System-like technology [39]. A minimally invasive approach would make intratumoral administration of 166HoAcAcMS suitable for treatment of patients for whom surgical resection is considered inappropriate.

Conclusions

The present study demonstrates that intratumoral administration of 166HoAcAcMS is a promising novel minimally invasive treatment of kidney cancer. Tumor growth was arrested and no signs of radiation damage outside the treatment zone were observed. Importantly, multimodality imaging including CT, SPECT and MRI of small amounts of 166HoAcAcMS was feasible. This will lead to an improved therapy evaluation and follow-up and provides a fundamental advantage over current therapies.

Acknowledgments

The authors would like to thank M.J.J. Koster-Ammerlaan for the neutron irradiations, R. de Roos, and L. Hubens for technical assistance, J. IJmker for ICP-MS measurements, R.M. Ramakers for his help with the U-CT and U-SPECT image acquisition and R. Giles for critically reading the manuscript.

Author Contributions

Conceived and designed the experiments: JJMJ SGCK WB JLHRB JFWN. Performed the experiments: JJMJ SGCK WB ME PRS FJB HWAMJ DRAU JGWK PRL WEH JFWN ADvhS. Analyzed the data: JJMJ SGCK WB JFWN FJB JGWK JLHRB. Contributed reagents/materials/analysis tools: JJMJ SGCK WB ME PRS FJB HWAMJ DRAU JGWK PRL WEH JFWN ADvhS JLHRB. Wrote the paper: SGCK WB.

Citation: Bult W, Kroeze SGC, Elschot M, Seevinck PR, Beekman FJ, de Jong HWAM, et al. (2013) Intratumoral Administration of Holmium-166 Acetylacetonate Microspheres: Antitumor Efficacy and Feasibility of Multimodality Imaging in Renal Cancer. PLoS ONE 8(1): e52178. https://doi.org/10.1371/journal.pone.0052178

References

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108.

2. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK (2006) Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98: 1331–1334.

3. Kutikov A, Egleston BL, Wong YN, Uzzo RG (2010) Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 28: 311–317.

4. Santos Arrontes D, Fernandez Acenero MJ, Garcia Gonzalez JI, Martin Munoz M, Paniagua Andres P (2008) Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol 179: 857–861.

5. Lane BR, Abouassaly R, Gao T, Weight CJ, Hernandez AV, et al. (2010) Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 116: 3119–3126.

6. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, et al. (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58: 398–406.

7. Heuer R, Gill IS, Guazzoni G, Kirkali Z, Marberger M, et al. (2010) A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur Urol 57: 223–232.

8. Muto G, Castelli E, Migliari R, D'Urso L, Coppola P, et al. (2011) Laparoscopic Microwave Ablation and Enucleation of Small Renal Masses: Preliminary Experience. Eur Urol 60: 173–6.

9. Kerkhof EM, Raaymakers BW, van Vulpen M, Zonnenberg BA, Bosch JL, et al. (2011) A new concept for non-invasive renal tumour ablation using real-time MRI-guided radiation therapy. BJU Int 107: 63–68.

10. MacKie S, de Silva S, Aslan P, Ladd L, Houang M, et al. (2011) Super selective radio embolization of the porcine kidney with 90yttrium resin microspheres: a feasibility, safety and dose ranging study. J Urol 185: 285–290.

11. Gao W, Liu L, Liu ZY, Wang Y, Jiang B, et al. (2010) Intratumoral injection of 32P-chromic phosphate in the treatment of implanted pancreatic carcinoma. Cancer Biother Radiopharm 25: 215–224.

12. Coldwell D, Sangro B, Salem R, Wasan H, Kennedy A (2012) Radioembolization in the Treatment of Unresectable Liver Tumors: Experience Across a Range of Primary Cancers. Am J Clin Oncol 35: 167–77.

13. Vente MA, Wondergem M, van der Tweel I, van den Bosch MA, Zonnenberg BA, et al. (2009) Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 19: 951–959.

14. Tian JH, Xu BX, Zhang JM, Dong BW, Liang P, et al. (1996) Ultrasound-guided internal radiotherapy using yttrium-90-glass microspheres for liver malignancies. J Nucl Med 37: 958–963.

15. Lin WY, Tsai SC, Hsieh JF, Wang SJ (2000) Effects of 90Y-microspheres on liver tumors: comparison of intratumoral injection method and intra-arterial injection method. J Nucl Med 41: 1892–1897.

16. Bult W, Seevinck PR, Krijger GC, Visser T, Kroon-Batenburg LM, et al. (2009) Microspheres with ultrahigh holmium content for radioablation of malignancies. Pharm Res 26: 1371–1378.

17. Nijsen JF, Zonnenberg BA, Woittiez JR, Rook DW, Swildens-van Woudenberg IA, et al. (1999) Holmium-166 poly lactic acid microspheres applicable for intra-arterial radionuclide therapy of hepatic malignancies: effects of preparation and neutron activation techniques. Eur J Nucl Med 26: 699–704.

18. Seevinck PR, Seppenwoolde JH, de Wit TC, Nijsen JF, Beekman FJ, et al. (2007) Factors affecting the sensitivity and detection limits of MRI, CT, and SPECT for multimodal diagnostic and therapeutic agents. Anticancer Agents Med Chem 7: 317–334.

19. Seevinck PR, van de Maat GH, de Wit TC, Vente MA, Nijsen JF, et al. (2012) Magnetic resonance imaging-based radiation-absorbed dose estimation of 166Ho microspheres in liver radioembolization. Int J Radiat Oncol Biol Phys 83: 437–444.

20. Zielhuis SW, Nijsen JF, Figueiredo R, Feddes B, Vredenberg AM, et al. (2005) Surface characteristics of holmium-loaded poly(L-lactic acid) microspheres. Biomaterials 26: 925–932.

21. Bult W, de Leeuw H, Steinebach OM, van der Bom MJ, Wolterbeek HT, et al. (2012) Radioactive Holmium Acetylacetonate Microspheres for Interstitial Microbrachytherapy: An In Vitro and In Vivo Stability Study. Pharm Res 29: 827–36.

22. van der Have F, Vastenhouw B, Ramakers RM, Branderhorst W, Krah JO, et al. (2009) U-SPECT-II: An Ultra-High-Resolution Device for Molecular Small-Animal Imaging. J Nucl Med 50: 599–605.

23. Branderhorst W, Vastenhouw B, Beekman FJ (2010) Pixel-based subsets for rapid multi-pinhole SPECT reconstruction. Phys Med Biol 55: 2023–2034.

24. van der Have F, Vastenhouw B, Rentmeester M, Beekman FJ (2008) System calibration and statistical image reconstruction for ultra-high resolution stationary pinhole SPECT. IEEE Trans Med Imaging 27: 960–971.

25. Bolch WE, Bouchet LG, Robertson JS, Wessels BW, Siegel JA, et al. (1999) MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions–radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med 40: 11S–36S.

26. Hendricks JSM, McKinney GW, Waters LS, Roberts TL, Egdorf HW, et al.. (2005) MCNP Extention, Version 2.5.0. Los Alamos: Los Alamos National Laboratory Report. LA-UR-05-2675: 1–70 p.

27. Forrer F, Rolleman E, Bijster M, Melis M, Bernard B, et al. (2007) From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99 m)Tc-DMSA-SPECT and molecular imaging. Cancer Biother Radiopharm 22: 40–49.

28. Madrazo A, Suzuki Y, Churg J (1969) Radiation nephritis: acute changes following high dose of radiation. Am J Pathol 54: 507–527.

29. Vente MA, Nijsen JF, de Wit TC, Seppenwoolde JH, Krijger GC, et al. (2008) Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly(L-lactic acid) microspheres in healthy pigs. Eur J Nucl Med Mol Imaging 35: 1259–1271.

30. D'Asseler Y (2009) Advances in SPECT imaging with respect to radionuclide therapy. Q J Nucl Med Mol Imaging 53: 343–347.

31. de Wit TC, Xiao J, Nijsen JF, van het Schip FD, Staelens SG, et al. (2006) Hybrid scatter correction applied to quantitative holmium-166 SPECT. Phys Med Biol 51: 4773–4787.

32. Vanhove C, Defrise M, Bossuyt A, Lahoutte T (2009) Improved quantification in single-pinhole and multiple-pinhole SPECT using micro-CT information. Eur J Nucl Med Mol Imaging 36: 1049–1063.

33. O'Donoghue J (2004) Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm 19: 378–387.

34. Zielhuis SW, Nijsen JF, Seppenwoolde JH, Bakker CJ, Krijger GC, et al. (2007) Long-term toxicity of holmium-loaded poly(L-lactic acid) microspheres in rats. Biomaterials 28: 4591–4599.

35. Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, et al. (2010) Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. J Exp Clin Cancer Res 29: 70.

36. Smits MLJ, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, et al. (2012) Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol 13: 1025–34.

37. Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR (2005) Radiofrequency ablation of renal cell carcinoma: part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol 185: 64–71.

38. Luboldt W, Pinkert J, Matzky C, Wunderlich G, Kotzerke J (2009) Radiopharmaceutical tracking of particles injected into tumors: a model to study clearance kinetics. Curr Drug Deliv 6: 255–260.

39. Hung AJ, Ma Y, Zehnder P, Nakamoto M, Gill IS, et al. (2012) Percutaneous radiofrequency ablation of virtual tumours in canine kidney using Global Positioning System-like technology. BJU Int 109: 1398–403.